
Personalis rose 46.7% from $9.73 to $14.27, ahead of the S&P 500's +4.7%. Its worst day was Mar 12 (−17.1%), and its low came Apr 29 at $5.04.
Nov 21, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Personalis shares rose 14.1%, while the S&P 500 rose 0.6%.
+14.1% · S&P 500 +0.6%
Personalis shares rose 16.6%, while the S&P 500 rose 0.5%.
+16.6%, the year's best day · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
EPS of $-0.26 beat the $-0.29 estimate on $17.3M revenue (est. $17.5M); FY revenue guidance of $78.0M–$80.0M against the $81.0M consensus.
+0.3% · S&P 500 −0.5%
The prospective study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer across more than 24 leading US cancer centers.
−17.1%, the year's worst day · S&P 500 −1.5%
Personalis closed at its lowest level of the year, 48.2% below where the year started.
−8.4% · S&P 500 0.0%
EPS of $-0.29 missed the $-0.27 estimate on $15.5M revenue (est. $14.5M); FY revenue guidance of $78.0M–$80.0M against the $78.8M consensus.
−0.2% · S&P 500 +0.8%
Personalis shares rose 15.7%, while the S&P 500 rose 0.6%.
+15.7% · S&P 500 +0.6%
EPS of $-0.30 missed the $-0.26 estimate on $22.4M revenue (est. $17.1M).
0.0% · S&P 500 −0.2%
Personalis closed at its highest level of the year, 88.9% above where the year started.
+8.9% · S&P 500 +0.4%
EPS of $-0.32 missed the $-0.25 estimate on $25.6M revenue (est. $21.7M).
−1.5% · S&P 500 −4.4%
Where it ended: a close of $14.27 on Nov 20, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.24, revenue est. $25.2M).
Nothing in the past 12 months.
All PSNL dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PSNL and SPY from Benzinga historical bars. Not investment advice.